Gene Target Therapy for Male Breast Cancer

Male breast cancer, an infrequent yet significant condition, accounts for 1% of all breast cancer diagnoses. Traditional treatments for male breast cancer often mirror those used in female cases, primarily due to limited research focusing on men. However, advancements in gene-targeted therapies have introduced more precise and effective treatment options [1]. Gene-targeted therapy aims to identify and combat specific genetic mutations or proteins that promote cancer growth in male breast cancer. One prevalent target is the HER2 protein. In cases where cancer cells overexpress HER2, monoclonal antibodies such as Trastuzumab (Herceptin) and Pertuzumab (Perjeta) are utilized. These drugs bind directly to the HER2 proteins, blocking their activity and hindering cancer cell proliferation [2]. Hormonal influences also play a role in male breast cancer, with specific tumors exhibiting hormone receptor-positive characteristics. Targeted treatments for these types aim to obstruct hormone receptors or decrease hormone levels. Tamoxifen, a selective estrogen receptor modulator (SERM), is commonly prescribed due to its efficacy in treating hormone receptor-positive breast cancer in both men and women. Genetic mutations, particularly in BRCA1 and BRCA2 genes, are linked to around 20% of male breast cancer cases. This genetic predisposition has led to the development of PARP inhibitors like Olaparib. These drugs exploit the weaknesses in cancer cells caused by these mutations, providing targeted treatment options [3]. Innovative treatment methods like Antibody-Drug Conjugates (ADCs) combine monoclonal antibodies with chemotherapy agents. The antibodies direct the chemotherapy specifically to cancerous cells, minimizing damage to healthy tissues. Despite the promising outlook of gene-targeted therapies, they come with specific side effects distinct from traditional chemotherapy. For instance, HER2-targeted treatments can lead to heart issues, while hormone therapies may result in menopausal-like symptoms.